🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

Published 16/01/2024, 13:51
© Reuters.  Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
SYK
-
MPC
-
CCI
-
ABBV
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. (NYSE: CCI) as her final trade.

Crown Castle, last month, announced a comprehensive review of its Fiber business and the addition of two new independent directors to the company's board.

Also Read: 'Business Insider Is Toast:' Bill Ackman Vows To 'Unleash Hell' In Lawsuit Against Media Site Over Plagiarism Claims Against Wife

Joseph Terranova of Virtus Investment Partners picked Marathon Petroleum Corporation (NYSE: MPC), as energy equities last year were one of the leaders

Marathon Petroleum recently named Maryann Mannen as President and John Quaid as Executive Vice President and CFO.

Don’t forget to check out our premarket coverage here

Brenda Vingiello of Sand Hill Global Advisors said Stryker Corporation (NYSE: SYK) had a great last year and is poised for another great year.

On Friday, RBC Capital analyst Shagun Singh maintained Stryker with an Outperform rating and raised the price target from $315 to $345.

Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE: ABBV) has a great valuation and dividend yield.

AbbVie recently announced a strategic collaboration with Umoja Biopharma to develop novel In-Situ CAR-T cell therapies.

Price Action: Crown Castle shares slipped 0.01% to close at $112.71, while Marathon Petroleum gained 1.3% to close at $157.46 on Friday. Stryker gained 1.3% to $312.90, while AbbVie gained by 0.1% to $162.40 during Friday’s session.

Check This Out: Qualcomm, NetApp And 2 Other Stocks Insiders Are Selling

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.